single invest


Reapplix specializes in the biological treatment and management of diabetic foot ulcers. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate wound healing of chronic diabetic foot ulcers.

Reapplix has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. Reapplix is one of more than 500 companies that Accelerace already have accelerated.

Related startups